Advertisement

Topics

Novartis gets EU nod for potential blockbuster breast cancer drug

04:20 EDT 24 Aug 2017 | Pharmafile

Novartis has released that it has received marketing approval from the European Commission for its drug for the treatment of breast cancer, Kisqali. The drug has been approved for use in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negatie (HR+/HER2-) locally advanced or metastatic breast cancer as a first-line treatment.

read more

Original Article: Novartis gets EU nod for potential blockbuster breast cancer drug

NEXT ARTICLE

More From BioPortfolio on "Novartis gets EU nod for potential blockbuster breast cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...